U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H20N4
Molecular Weight 280.3675
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of A-582941 FREE BASE

SMILES

CN1C[C@H]2CN(C[C@H]2C1)C3=NN=C(C=C3)C4=CC=CC=C4

InChI

InChIKey=GTMRUYCIJSNXGB-GASCZTMLSA-N
InChI=1S/C17H20N4/c1-20-9-14-11-21(12-15(14)10-20)17-8-7-16(18-19-17)13-5-3-2-4-6-13/h2-8,14-15H,9-12H2,1H3/t14-,15+

HIDE SMILES / InChI
Molecular Formula C17H20N4
Molecular Weight 280.3675
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/17898229 | http://adisinsight.springer.com/drugs/800020139

A-582941 was found to exhibit high-affinity binding and agonism at alpha-7 nicotinic acetylcholine receptor (α7-nAChR), with acceptable pharmacokinetic properties and excellent distribution to the central nervous system. In vitro and in vivo studies indicated that A-582941 activates signaling pathways known to be involved in cognitive function such as ERK1/2 and CREB phosphorylation. A-582941 enhanced cognitive performance in behavioral assays including the monkey delayed matching-to-sample, rat social recognition, and mouse inhibitory avoidance models that capture domains of working memory, short-term recognition memory, and long-term memory consolidation, respectively. AbbVie is developing α7-nAChR agonists including A-582941 as neuroprotective agents for the treatment of cognitive disorders such as Alzheimer's disease and schizophrenia. Development is at the preclinical stage.

CNS Activity

CNS Active
4002
Curator's Comment: A-582941 is CNS penetrant and active in animals. No human data available.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 6.17 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.
2014-02
In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys.
2010-02-01
Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice.
2009-01-05
The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: Differential effects in the juvenile and adult rat.
2008-06-23
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.
2008
Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.
2007-09-26
Patents

Patents

20050065178
2
20050101602
3
20080064695
3
20080070929
3
20080275048
2
20090163470
2
JP2007521323A
2

Sample Use Guides

In Vivo Use Guide
Administration of A-582941 (1 μmol/kg, i.p.) in mouse produced maximal levels in brain (286 ng/g at 0.33 h) that were 11-fold higher than the plasma C max (26 ng/ml at 0.25 h). This distribution ratio was maintained over an 8 h period, as drug cleared from brain and plasma with t 1/2 = 2.5–3.2 h. Similarly, in rat, A-582941 partitions with approximate sixfold higher levels in brain versus plasma after intraperitoneal dosing at 2–20 μmol/kg. Over this dose range, linear pharmacokinetics was observed, with brain C max (normalized to a 1 μmol/kg dose) averaging 363 ng/g and maximum plasma levels of 62 ng/ml.
Route of Administration: Intraperitoneal
In Vitro Use Guide
A-582941 increases ERK1/2 phosphorylation via α7 nAChRs in a concentration dependent manner EC50 = 95 nM
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:37:17 GMT 2025
Edited
by admin
on Mon Mar 31 22:37:17 GMT 2025
Record UNII
2MUW0L49BN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
2-METHYL-5-(6-PHENYLPYRIDAZIN-3-YL)OCTAHYDROPYRROLO(3,4-C)PYRROLE
Preferred Name English
A-582941 FREE BASE
Common Name English
PYRROLO(3,4-C)PYRROLE, OCTAHYDRO-2-METHYL-5-(6-PHENYL-3-PYRIDAZINYL)-
Systematic Name English
PYRROLO(3,4-C)PYRROLE, OCTAHYDRO-2-METHYL-5-(6-PHENYL-3-PYRIDAZINYL)-, (3AR,6AS)-REL-
Systematic Name English
Code System Code Type Description
FDA UNII
2MUW0L49BN
Created by admin on Mon Mar 31 22:37:17 GMT 2025 , Edited by admin on Mon Mar 31 22:37:17 GMT 2025
PRIMARY
CAS
848591-89-9
Created by admin on Mon Mar 31 22:37:17 GMT 2025 , Edited by admin on Mon Mar 31 22:37:17 GMT 2025
PRIMARY
CAS
1173179-34-4
Created by admin on Mon Mar 31 22:37:17 GMT 2025 , Edited by admin on Mon Mar 31 22:37:17 GMT 2025
ALTERNATIVE
PUBCHEM
44190553
Created by admin on Mon Mar 31 22:37:17 GMT 2025 , Edited by admin on Mon Mar 31 22:37:17 GMT 2025
PRIMARY
Related Record Type Details
NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-7
TARGET->PARTIAL AGONIST
ACTS AS PARTIAL AGONIST; ACTIVATES ERK1/2 AND CREB PHOSPHORYLATION; ENHANCES COGNITIVE PERFORMANCE. ; ALPHA 7 IN VITRO DATA: Ki = 10.8 nM
Related Record Type Details
Structure of A-582941 FREE BASE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966